EF5

DRUG13 trials

Sponsors

National Cancer Institute (NCI), University Health Network, Toronto, Duke University, David M. Brizel, MD, Gynecologic Oncology Group

Conditions

Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Central Nervous System Germ Cell TumorAdult Choroid Plexus TumorAdult CraniopharyngiomaAdult Diffuse Astrocytoma

Early Phase 1

To Evaluate the Characteristics of a Breast Cancer

WithdrawnNCT01055678

Mark DewhirstBreast Cancer

Start: 2010-01-31End: 2011-12-31Updated: 2012-12-17

Phase 1

EF5 in Treating Patients With Solid Tumors

CompletedNCT00003282

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 1998-03-31Updated: 2013-01-16

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

TerminatedNCT00004261

University Health Network, TorontoBreast Cancer, Cervical Cancer, Head and Neck Cancer +2

Start: 1999-12-31Updated: 2018-02-22

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

TerminatedNCT00110032

National Cancer Institute (NCI)Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma +24

Start: 2005-06-30Updated: 2013-01-16

Imaging and Biomarkers of Hypoxia in Solid Tumors

TerminatedNCT01123005

Stanford UniversityNeoplasms

Start: 2010-12-31End: 2015-08-21Updated: 2017-11-06

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

CompletedNCT01163487

Daniel T. ChangHead and Neck Cancer, Head and Neck Cancers

Start: 2010-08-31End: 2016-02-29Updated: 2022-06-16

Phase 2

EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

CompletedNCT00041028

Duke UniversityLung Cancer

Start: 2002-05-31End: 2014-04-30Target: 60Updated: 2015-05-01

EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer

CompletedNCT00049140

David M. Brizel, MDHead and Neck Cancer

Start: 2002-08-31Updated: 2014-07-25

EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

CompletedNCT00107445

National Cancer Institute (NCI)Primary Peritoneal Cavity Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer +13

Start: 2005-02-28Updated: 2013-01-16

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

CompletedNCT02154399

National Cancer Institute (NCI)Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma +3

Start: 2002-05-31End: 2014-04-30Updated: 2015-04-13

Unknown Phase

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

CompletedNCT00049231

Gynecologic Oncology GroupCervical Cancer

Start: 2003-06-30End: 2005-08-31Updated: 2013-06-24

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

TerminatedNCT00087191

National Cancer Institute (NCI)Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer +68

Start: 2004-05-31Updated: 2013-01-16

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

TerminatedNCT00896961

National Cancer Institute (NCI)Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma +3

Start: 2001-08-31Updated: 2013-01-16